Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roswitha Bussar-Maatz

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 24, 2012
[Localised prostate cancer: the PREFERE trial]Michael Stöckle, Roswitha Bussar-Maatz
Der Urologe. Ausg. A|February 25, 2016
[PREFERE - Study on the rise]Carsten-H Ohlmann, Michael Stöckle, Peter Albers, et al.
Journal of Cancer Research and Clinical Oncology|September 5, 2020
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)Thomas Wiegel, Peter Albers, Detlef Bartkowiak, et al.
World Journal of Urology|March 20, 2020
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trialPeter Albers, Thomas Wiegel, Heinz Schmidberger, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|July 24, 2012
[Localised prostate cancer: the PREFERE trial]Michael Stöckle, Roswitha Bussar-Maatz
Der Urologe. Ausg. A|February 25, 2016
[PREFERE - Study on the rise]Carsten-H Ohlmann, Michael Stöckle, Peter Albers, et al.
Journal of Cancer Research and Clinical Oncology|September 5, 2020
Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)Thomas Wiegel, Peter Albers, Detlef Bartkowiak, et al.
World Journal of Urology|March 20, 2020
Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trialPeter Albers, Thomas Wiegel, Heinz Schmidberger, et al.
Pageof 1